Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact
Whitepapers & Reports

Technical Note for the Viability of DE20 and DE50 Droplets

19 September 2023
Open document in a new tab

Related Resources

NextGen Biomed's 25 for 25

Curated by the NextGen Biomed Academic Steering Group, this collection reflects a year of rapid scientific progress across biologics, immunotherapy, cell & gene therapy, oligonucleotides, peptides, and vaccines.
Read More

Precision Medicine's 25 for 25

Our Top 25 R&D Leaders of ’25 eBook brings together the most influential thinkers, innovators, and trailblazers shaping the future of targeted therapies, spatial biology, biomarkers, multi-omics, and AI‑driven discovery.
Read More

Cell Therapy for Solid Tumors: An Innovative Approach to Cancer Treatment

Cell therapy for solid tumours is an innovative cancer treatment that uses a patient's own immune cells or donor cells to fight cancer, but its effectiveness varies by tumour type and patient's immune system. Although it offers new hope, it poses risks such as cytokine release syndrome and neurotoxicity. Recent advancements have led to better targeting, combination therapies, and next-generation treatments, with future research aimed at improving safety, effectiveness, and accessibility, potentially revolutionising cancer care.
Read More

Advancing Melanoma Treatment: The FDA Gives Lifileucel The Greenlight in Historic Cell & Gene Therapy Breakthrough

The Food and Drug Administration (FDA) approved lifileucel, a one-of-a-kind T-cell therapy developed by Iovance Biotherapeutics for treating melanoma.
Read More